Arvanil | TRPV1 channel activator

Available Options

Size:PriceQuantity 
5 mg$40.00
25 mg$135.00
Request Quote / Bulk / Custom Size
Product Inquiry

Arvanil (128007-31-8) is a non-pungent capsaicin analog with antinociceptive and anti-inflammatory effects in vivo.1 It is an agonist at TRPV1 as well as CB1 (Ki = 0.25 – 0.52 μM), but not CB2.2,3 Caused high mitochondrial calcium flow in hepatocellular carcinoma cells, ultimately leading to ferroptosis.4 It induced FADD-dependent apoptosis in lymphoid Jurkat T-cells.5 Neuroprotective in rat excitotoxicity model.6

References/Citations:

  1. Janusz et al. (1993), 1. Analogs of capsaicin with antinociceptive and antiinflammatory activity; J. Med. Chem. 36 2595
  2. Lim et al. (2022), Highly Efficient Real-Time TRPV1 Screening Methodology for Effective Drug Candidates; ACS Omega 7 36441
  3. Di Marzo et al. (1998), Interactions between synthetic vanilloids and the endogenous cannabinoid system; FEBS Lett. 436 449
  4. Deng et al. (2024), Arvanil induces ferroptosis of hepatocellular carcinoma by binding to MICU1; Cancer Gene Ther. 31 148
  5. Sancho et al. (2003), The CB1/VR1 agonist arvanil induces apoptosis through an FADD/caspase-8-dependent pathway; Br. J. Pharmacol. 140 1035
  6. Veldhuis et al. (2003), Neuroprotection by the endogenous cannabinoid anandamide and arvanil against in vivo excitotoxicity in the rat: the role of vanilloid receptors and lipoxygenases; J. Neurosci. 23 4127
128007-31-8, arvanil, Arvanil supplier, N-vanillylarachidonamide, TRPV1 activator, TRPV1 agonist
Alternate Name:
Vanillylarachidonamide

Safety Data Sheet:

N/A

Product Data Sheet:

Download Product Data Sheet

Materials provided by Focus Biomolecules are for laboratory research use only and are not intended for human or veterinary applications. Please note that we do not sell to individuals and that all orders placed by non-research organizations will incur a $20 restocking/refund fee

Arvanil (128007-31-8) is a non-pungent capsaicin analog with antinociceptive and anti-inflammatory effects in vivo.1 It is an agonist at TRPV1 as well as CB1 (Ki = 0.25 – 0.52 μM), but not CB2.2,3 Caused high mitochondrial calcium flow in hepatocellular carcinoma cells, ultimately leading to ferroptosis.4 It induced FADD-dependent apoptosis in lymphoid Jurkat T-cells.5 Neuroprotective in rat excitotoxicity model.6

References/Citations:

  1. Janusz et al. (1993), 1. Analogs of capsaicin with antinociceptive and antiinflammatory activity; J. Med. Chem. 36 2595
  2. Lim et al. (2022), Highly Efficient Real-Time TRPV1 Screening Methodology for Effective Drug Candidates; ACS Omega 7 36441
  3. Di Marzo et al. (1998), Interactions between synthetic vanilloids and the endogenous cannabinoid system; FEBS Lett. 436 449
  4. Deng et al. (2024), Arvanil induces ferroptosis of hepatocellular carcinoma by binding to MICU1; Cancer Gene Ther. 31 148
  5. Sancho et al. (2003), The CB1/VR1 agonist arvanil induces apoptosis through an FADD/caspase-8-dependent pathway; Br. J. Pharmacol. 140 1035
  6. Veldhuis et al. (2003), Neuroprotection by the endogenous cannabinoid anandamide and arvanil against in vivo excitotoxicity in the rat: the role of vanilloid receptors and lipoxygenases; J. Neurosci. 23 4127